As of Nov 19, 2026, 1 of 1 active firms rate ELDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ELDN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.20 – $-0.20 · 1 analysts · -39% YoY
Next period, 1 analysts expect Eledon Pharmaceuticals Inc to earn $-0.20 a share (range $-0.20 – $-0.20), versus $-0.33 a year earlier. Full-year consensus is $-0.89, growing to $-0.76 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Eledon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELDN.
#1
Vamil Divan
Guggenheim · Rank #211
Buy
$8.00+296.0% to target
Overall win rate
48%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton ELDN
Overall win rate
35%
+ Follow
#3
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$9.00+345.5% to target
Overall win rate
34%
+ Follow
#4
Thomas Smith
Leerink Partners · Rank #412
Buy
$8.00+296.0% to target
Overall win rate
41%
+ Follow
#5
SS
Seema Sheoran
Rodman & Renshaw
Buy
$12.00+494.1% to target
Coverage
—
+ Follow
ELDN stock forecast FAQ
What is ELDN's average 12-month price target?+
The 1 active firms with a live target average $12.00 for Eledon Pharmaceuticals Inc over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is ELDN stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ELDN?+
1 active firms have a recognized rating on Eledon Pharmaceuticals Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ELDN?+
Among analysts who currently cover ELDN, Vamil Divan of Guggenheim has the strongest overall Quantellect track record (Rank #211). Their current call is Buy with a $8.00 target.
What is Eledon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.20 – $-0.20) across 1 analysts. Full-year EPS is projected at $-0.89, rising to $-0.76 the following year.
How much revenue is Eledon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ELDN lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ELDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELDN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.